Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CHKA | P35790 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.32 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.32 |
| ▸ | PHGDH | O43175 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2186109 | 0.75 | CA2 (0.43) | CA2CA12CA1CA9CHKA | |
| SCHEMBL15334463 | 0.72 | — | — | |
| SCHEMBL9737097 | 0.71 | CA2 (0.39) | CA2CA12CA1CA9CHKA | |
| SCHEMBL28191935 | 0.69 | CA2 (0.46) | CA2CA12CA1CA9CHKA | |
| SCHEMBL21912690 | 0.69 | CA2 (0.39) | CA2CA12CA1CA9CHKA | |
| Piperazine SCHEMBL28191934 | 0.68 | CA2 (0.44) | CA2CA12CA1CA9CHKA | |
| SCHEMBL19372355 | 0.67 | — | — | |
| SCHEMBL6899581 | 0.67 | CA2 (0.38) | CA2CA12CA1CA9CHKA | |
| SCHEMBL277853 | 0.67 | CA2 (0.48) | CA2CA12CA1CA9CHKA | |
| SCHEMBL2942429 | 0.66 | CA2 (0.46) | CA2CA12CA1CA9CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350022-B1 | NEW BENZIMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2013-11-20 | — | — | EP | disclosed |
| EP-2321282-B1 | NEW BENZIMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2013-03-27 | — | — | EP | disclosed |
| US-8143422-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8088930-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-2350022-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-08-03 | — | — | EP | disclosed |
| EP-2321282-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010043513-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-04-22 | — | — | WO | disclosed |
| US-20100093818-A1 | BENZIMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-04-15 | — | — | US | disclosed |
| WO-2010028981-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-18 | — | — | WO | disclosed |
| US-20100063101-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-11 | — | — | US | disclosed |
| EP-1539746-B1 | N-SUBSTITUTED-1H-INDOL-5-PROPIONIC ACID COMPOUNDS AS PPAR AGONISTS USEFUL FOR THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2006-11-15 | — | — | EP | disclosed |
| US-7098228-B2 | e.g., 3-{1-[2-(3,5-Dimethoxy-phenyl)-5-methyl-oxazol-4-ylmethyl]-1H-indol-4-yl}-2-ethoxy-propionic acid ethyl ester; treating non-insulin dependent diabetes mellitus; PPAR receptor activation | HOFFMANN-LA ROCHE INC. (US) | 2006-08-29 | — | — | US | disclosed |
| EP-1567523-A1 | INDOLYL DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2005-08-31 | — | — | EP | disclosed |
| EP-1539746-A1 | N-SUBSTITUTED-1H-INDOL-5-PROPIONIC ACID COMPOUNDS AS PPAR AGONISTS USEFUL FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-15 | — | — | EP | disclosed |
| US-6890947-B2 | Indolyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2005-05-10 | — | — | US | disclosed |
| WO-2004048371-A1 | INDOLYL DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2004-06-10 | — | — | WO | disclosed |
| US-20040106657-A1 | Indolyl derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-03 | — | — | US | disclosed |
| WO-2004024726-A1 | N-SUBSTITUTED-1H-INDOL-5-PROPIONIC ACID COMPOUNDS AS PPAR AGONISTS USEFUL FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-25 | — | — | WO | disclosed |
| US-20040053979-A1 | Indolyl derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-18 | — | — | US | disclosed |
| EP-0063747-B1 | 2-SUBSTITUTED OR UNSUBSTITUTED AMINOCARBONYLOXYALKYL-1,4-DIHYDROPYRIDINES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1987-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063101-A1 | NEW BENZIMIDAZOLE DERIVATIVES | CYP3A7, ECI1, CYP2B6 | CA2 1310/4885CA12 4180/4885CA1 4371/4885 |
| US-20040106657-A1 | Indolyl derivatives | GPR119, IRS1, INSR | CA2 2808/4885CA12 4280/4885CA1 4283/4885 |
| US-20040053979-A1 | Indolyl derivatives | UGT1A8, CYP2C8, UGT1A1 | CA2 3008/4885CA12 3289/4885CA1 3110/4885 |
| US-20100093818-A1 | BENZIMIDAZOLE DERIVATIVES | CYP2B6, CYP3A4, CYP2C19 | CA2 1174/4885CA12 3992/4885CA1 4354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.